Kinenza (Enzastaurin): Global Drug Overview & Outlook 2017-2026 - ResearchAndMarkets.com

DUBLIN--()--The "Kinenza" report has been added to ResearchAndMarkets.com's offering.

Kinenza (enzastaurin) is an oral serine/threonine kinase inhibitor that suppresses signaling of protein kinase C (PKC)-beta to induce cell apoptosis, reduce cell proliferation, and suppress tumor-induced angiogenesis.

Inhibition of PKC-beta also suppresses the phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT) pathway by preventing activation and phosphorylation of AKT, glycogen synthase kinase (GSK)-3, and ribosomal protein S6.

Research Outlook

Denovo Biopharma is developing Kinenza in combination with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) in high-risk diffuse large B-cell lymphoma (DLBCL) patients who express their proprietary, novel genetic biomarker Denovo Genomic Marker 1 (DGM1).

Eli Lilly previously halted clinical development of Kinenza in DLBCL and sold the asset to Denovo after the drug failed to meet its primary endpoint in the Phase III PRELUDE trial (ClinicalTrials.gov identifier: NCT00332202). This clinical failure, in addition to limited information on the prevalence and treatment response of DGM1-positive patients, cast doubt on the renewed market potential for Kinenza in DLBCL. Data from the Phase III ENGINE study are needed to better determine the outlook for this drug.

Key Topics Covered

  1. Drug Overview
  2. Product Profiles
  3. Kinenza : NHL: Diffuse large B-cell lymphoma (DLBCL)

List of Figures

Figure 1: Kinenza for diffuse large B-cell lymphoma - SWOT analysis

Figure 2: The authors drug assessment summary for Kinenza in diffuse large B-cell lymphoma

Figure 3: Kinenza sales for diffuse large B-cell lymphoma in the US, 2017-26

List of Tables

Table 1: Kinenza drug profile

Table 2: Kinenza pivotal trial data in diffuse large B-cell lymphoma

Table 3: Kinenza ongoing pivotal trial in diffuse large B-cell lymphoma

Table 4: Kinenza sales for diffuse large B-cell lymphoma in the US ($m), 2017-26

For more information about this report visit https://www.researchandmarkets.com/r/9pe2ho

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Oncology Drugs

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Oncology Drugs